NASDAQ:DARE - Dare Bioscience Stock Price, Forecast & News

Dare Bioscience's stock was trading at $1.01 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, DARE stock has decreased by 15.8% and is now trading at $0.85. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dare Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dare Bioscience.

Dare Bioscience is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Dare Bioscience.

Dare Bioscience Inc (NASDAQ:DARE) released its earnings results on Monday, March, 30th. The biotechnology company reported ($0.21) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.01. View Dare Bioscience's earnings history.

2 brokerages have issued 12-month price targets for Dare Bioscience's stock. Their forecasts range from $3.00 to $4.00. On average, they expect Dare Bioscience's stock price to reach $3.50 in the next year. This suggests a possible upside of 311.8% from the stock's current price. View analysts' price targets for Dare Bioscience.

Press coverage about DARE stock has trended neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Dare Bioscience earned a coverage optimism score of 0.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutDare Bioscience.

Some companies that are related to Dare Bioscience include Bellerophon Therapeutics (BLPH), Leap Therapeutics (LPTX), Cumberland Pharmaceuticals (CPIX), Alpine Immune Sciences (ALPN), Oramed Pharmaceuticals (ORMP), Processa Pharmaceuticals (PCSA), Catalyst Biosciences (CBIO), Enlivex Therapeutics (ENLV), Aridis Pharmaceuticals (ARDS), Oncolytics Biotech (ONCY), Vascular Biogenics (VBLT), VERONA PHARMA P/S (VRNA), Infinity Pharmaceuticals (INFI), Tiziana Life Sciences (TLSA) and American Brivision (Holding) (ABVC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dare Bioscience investors own include FuelCell Energy (FCEL), Novavax (NVAX), Catalyst Pharmaceuticals (CPRX), Tonix Pharmaceuticals (TNXP), Protalix Biotherapeutics (PLX), AVEO Pharmaceuticals (AVEO), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), BIOLINERX LTD/S (BLRX) and Opko Health (OPK).

Dare Bioscience trades on the NASDAQ under the ticker symbol "DARE."

Shares of DARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DARE stock can currently be purchased for approximately $0.85.

Dare Bioscience has a market capitalization of $14.18 million. The biotechnology company earns $-16,740,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Dare Bioscience employs 5 workers across the globe. View additional information about Dare Bioscience.

The official website for Dare Bioscience is http://www.darebioscience.com/.

Dare Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The biotechnology company can be reached via phone at 858-926-7655 or via email at [email protected]